Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Asieris Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
Product Name : Cevira
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2023
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Asieris Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Asieris Pharmaceuticals | Richard Wolf | Tigermed-Jyton
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 31, 2022
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Asieris Pharmaceuticals | Richard Wolf | Tigermed-Jyton
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : KARL STORZ Endoscopy-America
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 25, 2015
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : KARL STORZ Endoscopy-America
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Detection of Bladder Tumors After 30 Min Instillation of Hexvix
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 12, 2012
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Visonac
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2011
Lead Product(s) : Visonac
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 29, 2011
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Recipient : Oslo University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2011
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Recipient : Oslo University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2010
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Chloride
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 12, 2010
Lead Product(s) : Sodium Chloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable